Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus
nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with
curative intent for early disease, which must have included immunotherapy and chemotherapy as
part of the radical locoregional therapy (either adjuvant, neoadjuvant or both).